ID   LIM1215 IR
AC   CVCL_E7AP
SY   LIM 1215 IR
RX   CelloPub=CLPUB00787;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_80630; Irinotecan (Camptothecin-11; CPT-11).
CC   Sequence variation: Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Omentum; UBERON=UBERON_0003688.
DI   NCIt; C4349; Colon adenocarcinoma
DI   NCIt; C8494; Lynch syndrome
DI   ORDO; Orphanet_144; Lynch syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2574 ! LIM1215
SX   Male
AG   34Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   CelloPub=CLPUB00787;
RA   Dilber T.;
RT   "Establishment of irinotecan resistant LIM 1215 cell line and
RT   identification of gene expression changes for irinotecan resistance as
RT   well as discovering potential second line drugs reverting irinotecan
RT   resistance.";
RL   Thesis MSc (2024); Middle East Technical University; Ankara; Turkey.
//